Youcare Pharmaceutical Group Co Ltd
SSE:688658
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Youcare Pharmaceutical Group Co Ltd
Additional Paid In Capital
Youcare Pharmaceutical Group Co Ltd
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Youcare Pharmaceutical Group Co Ltd
SSE:688658
|
Additional Paid In Capital
¥2.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Additional Paid In Capital
¥12.9B
|
CAGR 3-Years
62%
|
CAGR 5-Years
31%
|
CAGR 10-Years
40%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Additional Paid In Capital
¥17.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
30%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Additional Paid In Capital
¥3.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
16%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Additional Paid In Capital
¥4.7B
|
CAGR 3-Years
76%
|
CAGR 5-Years
219%
|
CAGR 10-Years
N/A
|
|
Youcare Pharmaceutical Group Co Ltd
Glance View
Youcare Pharmaceutical Group Co Ltd has woven itself into the fabric of China’s pharmaceutical industry, standing out with its dedication to research, production, and distribution of a diverse array of healthcare products. Founded with the vision of improving health outcomes, Youcare Pharmaceuticals has strategically positioned itself within the highly competitive pharmaceutical landscape by investing heavily in innovation and quality control. With a robust R&D wing, the company channels significant resources into developing new medications and improving existing formulations, aiming to address gaps in the market and meet the pressing health needs of its population. This commitment to innovation helps Youcare stay abreast of emerging medical trends and continuously expand its product portfolio, which spans from prescription medications to over-the-counter products. The economic engine of Youcare is fueled by a well-integrated supply chain that seamlessly bridges production capabilities with widespread distribution networks. By maintaining control over these critical components, Youcare not only ensures the efficiency and reliability of its delivery but also fortifies its competitive edge in terms of cost and speed to market. This synergy is essential as it allows the company to efficiently manage production costs while adhering to the stringent regulatory standards that govern pharmaceuticals. Revenue streams are further diversified through strategic partnerships and collaborations, which enhance the company’s geographical footprint and market penetration. Consequently, Youcare Pharmaceutical Group not only strengthens its influence domestically but also draws in profits from international markets, establishing itself as a dynamic player in the global pharmaceutical industry.
See Also
What is Youcare Pharmaceutical Group Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
2.6B
CNY
Based on the financial report for Dec 31, 2025, Youcare Pharmaceutical Group Co Ltd's Additional Paid In Capital amounts to 2.6B CNY.
What is Youcare Pharmaceutical Group Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
0%
Over the last year, the Additional Paid In Capital growth was 0%.